Summary:
To determine the safety and tolerability of subjects with Fibromyalgia and moderate to severe renal dysfunction during 13 weeks of renally adjusted dosing of DS-5565 compared to placebo.
Qualified Participants Must:
• Be at least 18 years of age
•
Have no history of suicidal thoughts or actions
•
Have no conflicting pain conditions
Qualified Participants May Receive:
Compensation for time and travel expenses, study provided medication, physicals performed by a board certified physician and lab work.